TEPADINA 15 mg powder for concentrate for solution for infusion

DRUG3 trials

Sponsors

GPOH gGmbH, Institut Curie, Fondazione Telethon Ets, San Raffaele Hospital

Conditions

Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 geneRetinoblastomaatypical teratoid/rhabdoid tumours (ATRT)

Phase 1

A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor cell populations that contain CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA in children with autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene.

Not yet recruitingCTIS2024-518972-30-00

Fondazione Telethon Ets, San Raffaele HospitalAutosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

Target: 8Updated: 2025-08-06

Phase 2

RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated

Active, not recruitingCTIS2024-514844-10-00

Institut CurieRetinoblastoma

Start: 2010-03-18Target: 195Updated: 2025-07-01

Phase 3

An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy

RecruitingCTIS2022-501456-28-00

GPOH gGmbHatypical teratoid/rhabdoid tumours (ATRT)

Start: 2020-07-20Target: 301Updated: 2025-10-03